Involvement of IRAKs and TRAFs in anti-β²GPI/β²GPI-induced tissue factor expression in THP-1 cells

Summary

Our previous study has shown that Toll-like receptor 4 (TLR4) and its signalling pathway contribute to anti-β²-glycoprotein I/β²-glycoprotein I (anti-β²GPI/β²GPI)-induced tissue factor (TF) expression in human acute monocytic leukaemia cell line THP-1 and annexin A2 (ANX2) is involved in this pathway. However, its downstream molecules have not been well explored. In this study, we have established that interleukin-1 receptor-associated kinases (IRAKs) and tumour necrosis factor receptor-associated factors (TRAFs) are crucial downstream molecules of anti-β²GPI/β²GPI-induced TLR4 signaling pathway in THP-1 cells and explored the potential mechanisms of their self-regulation. Treatment of THP-1 cells with anti-β²GPI/β²GPI complex induced IRAKs and TRAFs expression and activation. Anti-β²GPI/β²GPI complex firstly induced expression of IRAK4 and IRAK1, then IRAK1 phosphorylation and last IRAK3 upregulation. In addition, anti-β²GPI/β²GPI complex simultaneously and acutely enhanced mRNA levels of TRAF6, TRAF4 and zinc finger protein A20 (A20), while chronically increased A20 protein level. Moreover, anti-β²GPI/β²GPI complex-induced IRAKs and TRAFs expression and activation were attenuated by knockdown of ANX2 by infection with ANX2-specific RNA interference lentiviruses (LV-RNAi-ANX2) or by treatment with paclitaxel, which inhibits TLR4 as an antagonist of myeloid differentiation protein 2 (MD-2) ligand. Furthermore, both IRAK1/4 inhibitor and a specific proteasome inhibitor MG-132 could attenuate TRAFs expression as well as TF expression induced by anti-β²GPI/β²GPI complex. In conclusion, our results indicate that IRAKs and TRAFs play important roles in anti-β²GPI/β²GPI-stimulated TLR4/TF signaling pathway in THP-1 cells and contribute to the pathological processes of antiphospholipid syndrome (APS).

Keywords

Anti-β²-glycoprotein I antibodies - β²-glycoprotein I - IRAKs - TRAFs - tissue factor

^* These authors contributed equally to this work.

• References

• 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
• 2 Oosting JD, Derksen RH, Blokzijl L. et al. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity--studies in a thrombosis model. Thromb Haemost 1992; 68: 278-284.
• 3 Amengual O, Atsumi T, Khamashta MA. et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-281.
• 4 Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104: 2353-2358.
• 5 Lambrianides A, Carroll CJ, Pierangeli SS. et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010; 184: 6622-6628.
• 6 Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66-74.
• 7 Owens 3rd AP, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost 2010; 104: 432-439.
• 8 Srinivasan R, Bogdanov VY. Alternatively spliced Tissue Factor: discovery, insights, clinical implications. Front Biosci 2011; 17: 3061-3071.
• 9 Ma K, Simantov R, Zhang JC. et al. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275: 15541-15548.
• 10 Sorice M, Longo A, Capozzi A. et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56: 2687-2697.
• 11 Raschi E, Borghi MO, Grossi C. et al. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008; 17: 937-942.
• 12 Alard JE, Gaillard F, Daridon C. et al. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol 2010; 185: 1550-1557.
• 13 Kobayashi K, Matsuura E, Liu Q. et al. A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001; 42: 697-709.
• 14 Lutters BC, Derksen RH, Tekelenburg WL. et al. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 2003; 278: 33831-33838.
• 15 Sikara MP, Routsias JG, Samiotaki M. et al. {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010; 115: 713-723.
• 16 Zhou H, Wang H, Li N. et al. Annexin A2 mediates anti-beta 2 GPI/beta 2 GPI-induced tissue factor expression on monocytes. Int J Mol Med 2009; 24: 557-562.
• 17 Zhou H, Yan Y, Xu G. et al. Toll-like receptor (TLR)-4 mediates anti-β(2) GPI/β(2) GPI-induced tissue factor expression in THP-1 cells. Clin Exp Immunol 2011; 163: 189-198.
• 18 Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145-151.
• 19 Kobayashi M, Saitoh S, Tanimura N. et al. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 2006; 176: 6211-6218.
• 20 Resman N, Vasl J, Oblak A. et al. Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 4 in activation by endotoxin. J Biol Chem 2009; 284: 15052-15060.
• 21 Gao Y, Fang X, Tong Y. et al. TLR4-mediated MyD88-dependent signaling pathway is activated by cerebral ischemia-reperfusion in cortex in mice. Biomed Pharmacother 2009; 63: 442-450.
• 22 Brown J, Wang H, Hajishengallis GN. et al. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res 2011; 90: 417-427.
• 23 Martin M, Böl GF, Eriksson A. et al. Interleukin-1-induced activation of a protein kinase co-precipitating with the type I interleukin-1 receptor in T cells. Eur J Immunol 1994; 24: 1566-1571.
• 24 Croston GE, Cao Z, Goeddel DV. NF-kappa B activation by interleukin-1 (IL-1) requires an IL-1 receptor-associated protein kinase activity. J Biol Chem 1995; 270: 16514-16517.
• 25 Wesche H, Gao X, Li X. et al. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 1999; 274: 19403-19410.
• 26 Kollewe C, Mackensen AC, Neumann D. et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem 2004; 279: 5227-5236.
• 27 Kobayashi K, Hernandez LD, Galán JE. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191-202.
• 28 Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
• 29 Deng L, Wang C, Spencer E. et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-361.
• 30 Boone DL, Turer EE, Lee EG. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5: 1052-1060.
• 31 Takeshita F, Ishii KJ, Kobiyama K. et al. TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF. Eur J Immunol 2005; 35: 2477-2485.
• 32 Di Simone N, Di Nicuolo F, D'Ippolito S. et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010; 83: 212-219.
• 33 Agar C, van Os GM, Mörgelin M. et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-1343.
• 34 Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005; 105: 1964-1969.
• 35 Zhou H, Ling S, Yu Y. et al. Involvement of annexin A2 in anti-beta2GPI /beta2GPI-induced tissue factor expression on monocytes. Cell Res 2007; 17: 737-739.
• 36 Romay-Penabad Z, Montiel-Manzano MG, Shilagard T. et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114: 3074-3083.
• 37 Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 2003; 11: 293-302.
• 38 Raschi E, Testoni C, Bosisio D. et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500.
• 39 Bohgaki M, Atsumi T, Yamashita Y. et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004; 16: 1633-1641.
• 40 Swisher JF, Burton N, Bacot SM. et al. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood 2010; 115: 549-558.
• 41 Zimmer SM, Liu J, Clayton JL. et al. Paclitaxel binding to human and murine MD-2. J Biol Chem 2008; 283: 27916-27926.
• 42 Resman N, Gradisar H, Vasl J. et al. Taxanes inhibit human TLR4 signaling by binding to MD-2. FEBS Lett 2008; 582: 3929-3934.
• 43 Eisenreich A, Celebi O, Goldin-Lang P. et al. Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel. Int Immunopharmacol 2008; 8: 307-311.
• 44 Noels H, Somers R, Liu H. et al. Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma. PLoS One 2009; 4: e4822
• 45 Jensen LE, Whitehead AS. Ubiquitin activated tumor necrosis factor receptor associated factor-6 (TRAF6) is recycled via deubiquitination. FEBS Lett 2003; 553: 190-194.
• 46 Opipari Jr AW, Hu HM, Yabkowitz R. et al. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992; 267: 12424-12427.
• 47 Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem 2009; 284: 8217-8221.
• 48 O'Reilly SM, Moynagh PN. Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. Biochem Biophys Res Commun 2003; 303: 586-593.
• 49 Heyninck K, Beyaert R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett 1999; 442: 147-150.
• 50 Turer EE, Tavares RM, Mortier E. et al. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med 2008; 205: 451-464.